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Abstract: Lung cancer remains the most frequently diagnosed cancer in the United States, excluding non-melanoma skin cancer. 
Non-small cell lung cancer (NSCLC) constitutes the majority (more than 80%) of lung cancer diagnoses. Systemic therapy, with either 
cytotoxic chemotherapy and/or targeted therapies, has been established to provide benefit to patients with NSCLC in both the adjuvant 
and advanced disease settings. Vinorelbine, a semi-synthetic vinca-alkaloid has been extensively tested alone and in combination with 
other cytotoxic or targeted agents in the treatment of NSCLC. Its safety has been well established with neutropenia, anemia, nausea, 
and vomiting being the most frequently encountered toxicities. The data defining the risks and benefits of vinorelbine in the treatment 
of NSCLC will be summarized.
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Introduction
In the United States, lung cancer is the second most 
commonly  diagnosed  cancer  in  men  and  women, 
surpassed only by prostate cancer in men, and breast 
cancer  in  women.  It  remains  the  leading  cause  of 
death in either sex. It is estimated that 222,520 people 
(116,750 men and 105,770 women) will be diagnosed 
with, and 157,300 people will die of lung cancer in 
2010.1,2 More than 80% of lung cancer is the   non-small 
cell type.3
The overall five-year survival of this disease is 
poor (less than 15%), related to the fact that 84% of 
patients are diagnosed at an advanced stage.   Non-small 
cell lung cancer (NSCLC) is considered curable only 
when diagnosed prior to the development of metasta-
sis and the 5-year overall survival is far better (86%) 
when the disease is diagnosed at the earliest stage. In 
total, 30% to 70% of patients who undergo resection 
will develop recurrence of the disease, which will be 
incurable for the vast majority. Thus, there is a need 
for effective adjuvant and palliative therapy for this 
disease.2,4,5
Platinum-based chemotherapy combinations have 
been  demonstrated  to  provide  a  small,  but  signifi-
cant  overall  survival  (OS)  advantage  of  5%  at  5 
years in patients with completely resected NSCLC.6 
  Vinorelbine is a vinca-alkaloid approved for the treat-
ment of NSCLC, which also has demonstrated activ-
ity  against  breast  and  ovarian  cancer.  Vinorelbine 
has been evaluated in NSCLC in the adjuvant and 
advanced settings as a single agent and in combina-
tion with other agents (typically a platinum or gem-
citabine) with modest success. In this article we will 
review the key clinical trials that have established the 
role of vinorelbine in the treatment of NSCLC.
Mechanism of Action, Metabolism  
and Pharmacokinetic Profile
Vinorelbine  (5′nor-anhydro-vinblastine)  is  a  semi-
synthetic  vinca-alkaloid  that  is  manufactured  from 
alkaloids extracted from the rosy periwinkle, Catharan-
thus roseus. It was first produced in 1979. Vinorelbine 
induces cytotoxicity by inhibiting the polymerization 
of tubulin dimers into microtubules, which in turn 
disrupts mitotic spindle formation and prevents cell 
division.  This  promotes  apoptosis  of  cancer  cells. 
Vinorelbine is selective for mitotic microtubules, 
with minimal activity on axonal or other microtubule 
classes. Therefore, it is less likely to produce neu-
rotoxicity  compared  to  non-selective  microtubule 
inhibitors.7–10
Vinorelbine can be administered both orally and 
intravenously.  The  absolute  bioavailability  of  oral 
vinorelbine is approximately 40%.11 It is widely dis-
tributed in the liver, spleen, kidneys and lungs, and 
has slow efflux from tissue. The drug is highly bound 
to plasma protein (80%–90%) and its volume of dis-
tribution is approximately 25.4 to 40 L/Kg. It mini-
mally crosses the blood brain barrier. The majority 
of vinorelbine metabolism occurs in the liver via the 
cytochrome P450, CYP3A4. The active metabolite 
of vinorelbine is deacetyl vinorelbine and the inac-
tive  metabolite  is  N-oxide  vinorelbine.  It  is  prin-
cipally excreted by the liver via the biliary system 
(70%–80%);  the  urinary  system  accounts  for  the 
remainder (18%–20%). The half life is approximately 
27.7 to 43.6 hours.12–14
The maximum tolerated dose (MTD) of vinorel-
bine was found to be 45 mg/m2 in phase I trials. The 
major dose limiting toxicity is grade 3 leukocytope-
nia, which has an onset at day 8–10 after each dose. 
Through experience in phase II and III clinical   trials, 
the optimal schedule of intravenous (IV) administra-
tion has been determined to be 25–30 mg/m2 on days 1 
and 8 of a 21 day cycle. There is insufficient data 
on the dosing of vinorelbine in patients with severe 
hepatic impairment, but it is recommended to reduce 
the dose based on the bilirubin level.   Recommended 
dose adjustments for neutropenia are listed in Table 1. 
Dose reductions are not necessary in elderly patients, 
in the absence of hepatic dysfunction or hematologic 
toxicity.14–17
 Extravasations injuries can be reduced with careful 
administration via central access and/or through use 
of a shortened duration of administration.   Intravenous 
N
N
N N
H
H
H
H
C2H5
C2H5
H3CO
H3C
C
C
·   2
OCH3
CH3
HO
HO H
H3CO
C
O O
OH HC
C
COOH
COOH
O
O
Figure  1.  Chemical  structure  of  vinorelbine  tartrate  (trade  name, 
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Table 1. Recommended dose adjustments of vinorelbine.15–18
Hepatic impairment Serum bilirubin 
#2 mg/dL: 
Recommended 
dose: 100% 
Serum bilirubin 
2.1–3 mg/dL: 
Recommended 
dose: 50% 
Serum bilirubin 
.3 mg/dL: 
Recommended 
dose: 25% 
Absolute Neutrophil Counts 
(ANC) on day of treatment 
ANC 1500 cells/mm3 
Recommended dose: 
100% of starting dose
ANC 1000–1499 cells/mm3 
Recommended dose: 50% 
of starting dose.
ANC 1000 cells/mm3 
a.   Hold and repeat cell count 
every week.
b.   If 3 consecutive ANCs 
,1000 cells/mm3, 
discontinue vinorelbine.
Neutropenic fever while on treatment or 2 consecutive 
weekly doses held because of neutropenia:
75% of starting dose for 
ANC $1500 cells/mm3
37.5% of starting dose for ANC 
1000–1499 cells/mm3
Neurotoxicity $grade 2: Discontinue treatment.
Dosage adjustment is not recommended for elderly patients in the absence of hepatic dysfunction or hematologic toxicity.
Dosage adjustment is not necessary for patients with renal impairment.
doses should be followed by at least 75–525 cc of 
normal saline or dextrose 5% water to reduce the inci-
dence of phlebitis and inflammation.18
Vinorelbine in Adjuvant Therapy
In  1995,  a  landmark  meta-analysis  was  published 
by  the  Non-small  Cell  Lung  Cancer  Collaborative 
Group,  suggesting  that  treatment  with  platinum-
based chemotherapy following complete resection of 
Stage I–III NSCLC provides a small, but significant 
survival advantage over best supportive care (BSC); 
the standard at that time.7 These data prompted inves-
tigators to conduct several prospective, randomized 
trials aimed at confirming these results. Vinorelbine 
with cisplatin (VC) was a doublet studied in most of 
these trials.
Two large trials that examined multiple platinum 
containing chemotherapy doublets in the adjuvant set-
ting, including the VC regimen, were the International 
Adjuvant Lung Cancer Trial (IALT) and the Big Lung 
Trial. The IALT was designed to evaluate the effect 
of cisplatin-based adjuvant chemotherapy on survival 
after complete resection of NSCLC. This was a large 
randomized trial involving a total of 1,867 patients 
who  received  cisplatin  (80–120  mg/m2)  combined 
with each institution’s choice of either etoposide or 
a vinca-alkaloid (56.6% received etoposide, 26.8% 
received vinorelbine, 11% received vinblastine, and 
5.8% received vindesine). After a median follow-up 
of 56 months, patients assigned to receive chemother-
apy had a significantly higher survival rate than those 
assigned to observation (44.5% vs. 40.4% at five years; 
hazard ratio {HR} for death = 0.86; 95% confidence 
interval {CI} = 0.76 to 0.98; P , 0.03). The patients 
who were assigned to receive chemotherapy also had 
a significantly higher disease-free survival (DFS) rate 
than those assigned to observation (39.4% vs. 34.3% 
at five years; HR = 0.83; 95% CI = 0.74 to 0.94; 
P , 0.003). After a median   follow-up of 90 months, 
the beneficial effects of adjuvant chemotherapy on 
overall  survival  persisted,  but  were  no  longer  sta-
tistically significant (HR = 0.91; 95% CI = 0.81 to 
1.02; P = 0.10). The DFS benefit remained signifi-
cant (HR = 0.88; 95% CI = 0.78 to 0.98; P = 0.02). 
The analysis of non-lung cancer deaths for the study 
period showed a HR of 1.34 (95% CI = 0.99 to 1.81; 
P = 0.06) in favor of observation. Out of 851 patients 
who received chemotherapy, 7 patients (0.8%) died 
from a therapy-related toxicity. The major grade 4 
adverse events were neutropenia, thrombocytopenia, 
and vomiting. The toxicities for the patients receiving 
vinorelbine were not reported separately.19,20
The Big Lung Trial was a large multicenter trial 
in  which  725  patients  with  completely  resected 
NSCLC were randomized to observation (n = 361) or 
  cisplatin-based chemotherapy (n = 364). The permitted 
chemotherapy regimens were as follows: MIC (Day 1: 
cisplatin 50 mg/m2, mitomycin 6 mg/m2, ifosfamide 
3 g/m2), MVP (Day 1: cisplatin 50 mg/m2, mitomycin 
6 mg/m2, vinblastine 6 mg/m2), NP (Day 1: cispla-
tin 80 mg/m2, vindesine 3 mg/m2; day 8:   vindesine 
3 mg/m2), and VC (Day 1: cisplatin 80 mg/m2 and 
vinorelbine 30 mg/m2; day 8 vinorelbine 30 mg/m2). 
Forty-three patients (22%) received the VC regimen. Faller and Pandit
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The trial was terminated early because of slow accrual 
after enrolling 381 patients. It failed to show an over-
all survival benefit for chemotherapy (HR 1.02; 95% 
CI, 0.77 to 1.35; P = 0.90). Toxicities for the VC arm 
were not reported separately.21
The VC combination was chosen for study as the sole 
adjuvant therapy regimen in two additional large ran-
domized trials: the National Cancer Institute of   Canada 
Clinical Trials Group’s (NCIC CTG) JBR.10 trial, and 
the Adjuvant Navelbine   International Trial Associa-
tion (ANITA) trial. In the JBR.10 trial, 482 patients 
with completely resected stage IB or stage II NSCLC 
underwent randomization to 4 cycles of vinorelbine 
(25 mg/m2 weekly) plus cisplatin (50 mg/m2 on days 1 
and 8, every 4 weeks) or observation.   Forty-five per-
cent of the patients had pathological stage IB disease 
and 55 percent had stage II. All patients had an ECOG 
performance status of 0 or 1. The JBR.10 trial dem-
onstrated  an  11%  absolute  improvement  in  overall 
survival at 5 years in favor of the chemotherapy com-
bination (HR = 0.78; 95% CI, 0.61 to 0.99; P = 0.04). 
The subset analysis by stage showed a significant ben-
efit for stage II patients (HR = 0.68; 95% CI, 0.50 to 
0.92; P = 0.01), but not for patients with Stage IB dis-
ease (HR = 1.03; 95% CI, 0.70 to 1.52; P = 0.87). At a 
median follow-up of 9.3 years, the benefit for adjuvant 
chemotherapy remained (HR = 0.78; 95% CI, 0.61 to 
0.99; P = 0.04). The most frequent grade 3 and 4 tox-
icities are listed in Table 2. There were two treatment 
related deaths; one from neutropenic sepsis and one 
from interstitial lung disease.22
The ANITA trial was a randomized, phase III study 
of patients with completely resected stage IB, II, and 
IIIA NSCLC. Eight hundred forty patients with stage 
IB-IIIA  NSCLC  from  101  centers  in  14  countries 
were  randomly  assigned  to  observation  (n  =  433) 
or  to  chemotherapy  (n  =  407)  with  vinorelbine 
(30 mg/m2 weekly) plus cisplatin (100 mg/m2 every 
4 weeks). After a median follow-up of 76 months 
(range 43–116), the median survival was 65.7 months 
(95% CI = 47.9–88.5) in the chemotherapy group and 
43.7 months (95% CI = 35.7–52.3) in the observation 
group. The adjusted risk for death was significantly 
reduced  in  the  patients  assigned  to    chemotherapy 
compared to the controls (HR = 0.80, 95% CI = 0.66–
0.96; P = 0.017). The overall survival at 5 years in 
the  chemotherapy  group  was  improved  by  8.6%. 
In a subsequent follow-up, the 7 year OS benefit was 
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maintained at 8.4%. There were seven (2%) treatment 
related deaths. Frequencies of grade 3 or higher tox-
icities are listed in Table 2. The most frequent hema-
tologic complications were neutropenia, anemia, and 
febrile neutropenia.
The Lung Adjuvant Cisplatin Evaluation (LACE) 
meta-analysis analyzed data from the 5 largest clini-
cal trials of adjuvant cisplatin-based chemotherapy 
in NSCLC conducted since the 1995 NSCLC meta-
analysis. This included the 4 trials described above, 
and one that did not incorporate vinorelbine. Data 
on 4,584 patients were examined with a median fol-
low-up of 5.2 years (range per trial, 4.7 to 5.9 years). 
1888 patients (41%) received the VC combination. 
There was a statistically significant OS benefit for 
adjuvant chemotherapy (HR = 0.89; 95% CI, 0.82 
to 0.96; P = 0.005), corresponding to a 5-year abso-
lute benefit of 5.4%, consistent with the results of the 
1995 meta-analysis.23 A prespecified subgroup analy-
sis of the VC regimen was subsequently reported. The 
authors found that the OS benefit of adjuvant che-
motherapy was significantly greater (P value for the 
interaction = 0.04) for the subgroup of patients who   
were randomized to VC vs. observation (HR 0.80, 
95% CI: 0.70–0.91, P , 0.001) than for the subgroup 
of patients randomized to other chemotherapy regi-
mens vs. observation (HR 0.95, 95% CI: 0.86–1.05, 
P = 0.33). The 5-year absolute OS benefit from adju-
vant chemotherapy was 8.9% in the VC subgroup 
(55.1% vs. 46.2%). This suggestion that the VC regi-
men is superior to other adjuvant chemotherapy regi-
mens previously evaluated supports its current use as 
a standard option for adjuvant therapy for NSCLC.24
As  use  of  the  VC  regimen  has  become  widely 
adopted in the adjuvant setting, more patients are being 
placed at risk of its potential late toxicities. Although 
there were no secondary malignancies reported in the 
above trials, one case of therapy-related acute myel-
ogenous leukemia with a MLL gene rearrangement, 
t(11;19)  (q23;  p13.3)  presenting  13  months  after 
completion of 4 cycles of VC has been reported.25
Vinorelbine in Combination  
with Radiation Therapy for Locally 
Advanced, Unresectable Disease
Dual modality therapy combining chemotherapy with 
radiation therapy is a potentially curative therapy for 
unresectable, stage III or less NSCLC. Vinorelbine 
is not a standard in this setting in the United States, 
but its use as a radiation sensitizing agent has been 
  examined in Japan.
Use of VC with thoracic radiation was determined 
to  be  safe  in  a  phase  I  trial  conducted  by  Sekine 
and colleagues. Eighteen patients with unresectable 
stage III NSCLC received the combination of cispla-
tin (80 mg/m2) on day 1 and vinorelbine (20 mg/m2 
in level 1, and 25 mg/m2 in level 2) on days 1 and 
8 every 4 weeks for four cycles along with concur-
rent thoracic radiation to a total dose of 60 Gy. As a 
caveat, the radiation was delivered in 2 Gy fractions 
once daily for 3 weeks followed by a rest of 4 days. 
It was then resumed for an additional 3 weeks. The 
most common grade 3–4 toxicities were neutropenia 
(77% for level one; 100% for level two), infection 
(31% for level one; 60% for level two), and anemia 
(23% for level 1, 20% for level 2). Dose-limiting tox-
icity was noted in 33% of the patients in level one and 
in 60% of the patients in level two.26
Based on these results, a phase II study of this reg-
imen was conducted in Japan with use of a modified 
cisplatin  dosing  regimen. Twenty-six  patients  with 
unresectable stage III NSCLC were treated with cispl-
atin (40 mg/m2) and vinorelbine (20 mg/m2) on days 1 
and 8 of a 4 week cycle for a total of 2 to 4 cycles. 
The concurrent radiation started on day 2 of the first 
chemotherapy cycle and was delivered at 2 Gy per 
fraction to a total dose of 60 Gy over 6 weeks. After a 
median follow-up of 14 months, the overall response 
rate  was  80.8%  (95%  CI,  60.6%–93.4%),  with  5 
(19.2%)  complete  responses.  The  median  survival 
time was found to be 23 months (range, 4–43 months) 
and overall survival rate at 1 and 2 years were 80% 
and 56%, respectively. The most common grade 3–4 
toxicities were neutropenia (84.6%), anemia (61.5%), 
infection (26.9%), esophagitis (7.7%), and pneumoni-
tis (7.7%). There were no treatment related deaths.27
The efficacy of the cisplatin and vinorelbine com-
bination with concurrent radiation for NSCLC has yet 
to be examined in a large, randomized clinical trial. 
The off-label use of this regimen cannot be recom-
mended based on available data.
Vinorelbine in the Treatment  
of Advanced or Metastatic NSCLC
The  landmark  meta-analysis  of  data  from  53  ran-
domized  trials  published  in  1995  by  the  NSCLC vinorelbine in the treatment of non-small cell lung cancer
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collaborative group indicated a survival benefit for 
chemotherapy  in  advanced  NSCLC  (patients  who 
have metastatic or recurrent disease or a malignant 
pleural effusion). It demonstrated an absolute 1-year 
survival benefit of 10% and a modest improvement 
in median survival of 1.5 months for patients treated 
with  cisplatin-containing  regimens  compared  with 
best supportive care alone.7 Since this publication, 
the current practice for treating patients with meta-
static disease has changed dramatically with the addi-
tion of several new agents and the now standard use 
of histology in guiding therapy. In the United States, 
vinorelbine is rarely used in the first line setting, with 
the exception being its use in combination with cis-
platin  and  cetuximab,  the  epidermal  growth  factor 
receptor (EGFR) antagonist, based on data that will 
described below.
Vinorelbine in the First-Line Setting 
for Advanced Disease
The  vinorelbine  and  cisplatin  (VC)  combination 
was first established as an effective regimen in the 
advanced setting in 1994 after demonstrating supe-
riority over a standard regimen at the time of cispla-
tin and vindesine. In a phase III trial, a total of 612 
patients with advanced NSCLC were randomized to 
receive  three  different  chemotherapeutic  regimens: 
vinorelbine  alone  (V),  VC  (vinorelbine  30  mg/m2 
weekly and cisplatin 120 mg/m2 on day 1 and 29 
and then every 6 weeks), or vindesine and cisplatin. 
The VC regimen was statistically superior to both V 
alone and the vindesine combination for response rate 
(30% vs. 14% vs. 19%), as well as median survival 
(40 weeks vs. 31 weeks vs. 32 weeks).28
This  led  to  the  Southwest  Oncology  Group’s 
trial  comparing  VC  to  the  combination  of  carbo-
platin with paclitaxel (PC). Two-hundred and two 
patients  with  advanced  disease  were  randomized 
to VC (vinorelbine 25 mg/m2 weekly and cisplatin 
100 mg/m2 on day 1 every 28 days) or PC (paclitaxel 
225 mg/m2 and carboplatin AUC 6 every 21 days). 
VC was found to be not statistically different to PC 
in regards to response rate (28% vs. 25%), median 
survival (8 months in both arms), and 1-year sur-
vival rate (38% vs. 36%). Grade 3 and 4 neutropenia 
was more common in the VC arm (76% vs. 57%), 
as was grade 3 nausea (18% vs. 7%). Grade 3 sen-
sory   neuropathy was statistically higher in the PC 
arm (13% vs. 3%). There was no difference observed 
between the two arms in quality of life.29
A four-arm cooperative study in Japan confirmed 
similar efficacy between the PC and VC regimens 
in  addition  to  demonstrating  the  non-inferiority  of 
VC to two additional platinum based regimens. In 
this study, 602 patients with advanced disease were 
randomized to receive one of 4 platinum doublets: 
VC  (vinorelbine  25  mg/m2  on  days  1  and  8  plus 
cisplatin  80  mg/m2  on  day  1  every  21  days),  PC 
(paclitaxel  200  mg/m2  and  carboplatin  at  an AUC   
of  6  min  Xmg/ml  every  21  days),  IC  (irinotecan   
60  mg/m2  on  days  1,  8,  and  15  plus  cisplatin 
80 mg/m2 on day 1 every 28 days), or GC (gemcit-
abine  1000  mg/m2  on  days  1  and  8  plus  cisplatin 
80 mg/m2 on day 1 every 21 days). There were no 
statistically  significant  differences  in  response  rate 
or overall survival between patients in the 4 groups. 
All four regimens were well tolerated, with the most 
common grade 3 or 4 toxicities encountered in the VC 
arm being neutropenia, (88%), leukocytopenia (67%; 
significantly  worse  than  IC),  anemia  (30%),  and 
anorexia (20%). The median survival in each group 
was as follows: 11.4 months for VC, 12.3 months for 
PC, 13.9 months for IC, and 14.0 months for GC.30
The Italian study by Gebbia et al. was designed 
to  determine  the  optimal  dosing  of  vinorelbine  in 
the VC combination. In this trial 278 patients with 
advanced NSCLC were randomized to receive either 
arm A: vinorelbine 25 mg/m2 on day 1, 8, and 15 with 
cisplatin 100 mg/m2 on day 1 of a 28 day cycle or arm 
B: vinorelbine 30 mg/m2 on day 1 and 8 with cisplatin 
80 mg/m2 on day 1 of a 21 day cycle. There were no 
differences between arm A and arm B in median time 
to progression (TTP) (4.5 vs. 4.6 months), overall 
response rate (ORR) (34% vs. 32%), or median OS 
(9.45 vs. 10 months). The incidence of severe neutro-
penia was significantly worse in Arm A (68% vs. 34%; 
P = 0.0001), as was the incidence of febrile neutro-
penia (12% vs. 5%; P = 0.026). Due to an increased 
rate of dose delays and omissions, the weekly regi-
men (arm A) resulted in a lower overall dose intensity 
of vinorelbine.31
The VC doublet, however, began to lose favor in 
the United States when the TAX 326 study group dem-
onstrated its inferiority to the combination of cispla-
tin with the newer taxane, docetaxel. Twelve hundred 
and  eighteen  patients  with  advanced  disease  were Faller and Pandit
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  randomized  to  receive  VC  (vinorelbine  25  mg/m2 
weekly and cisplatin 100 mg/m2 on day 1 every 28 days), 
docetaxel  75  mg/m2  every  21  days  with  cisplatin 
75 mg/m2 every 21 days (DC), or docetaxel 75 mg/m2 
every 21 days with carboplatin at an AUC of 6 every 
3 weeks (DCb). The patients who received DC had 
statistically superior outcomes in regards to median 
survival (11.3 months for DC vs. 10.1 months for VC; 
P = 0.044), ORR (31.6% vs. 24.5%; P = 0.029), and 
2-year survival rate (21% vs. 14%). There were no 
differences, however, in these variables between the 
VC and DCb groups. The rates of grade 3 to 4 anemia 
(24% for VC vs. 10.5% for DCb vs. 6.9% for DC), 
nausea (16.4% for VC vs. 6.2% for DCb vs. 9.9% 
for DC), and vomiting (16.2% for VC vs. 4.2% for 
DCb vs. 7.9% for DC) were higher in the VC group 
compared to DCb or DC (P , .01), whereas rate of 
neutropenia, febrile neutropenia, thrombocytopenia, 
and infection were similar amongst the three groups. 
Finally, patients treated with either docetaxel regimen 
scored consistently higher on quality of life scores 
than the VC treated patients.32
Vinorelbine as Switch Maintenance 
Therapy for Advanced Disease
The use of maintenance therapy following 4–6 cycles 
of initial systemic therapy has emerged as a popular 
strategy for improving progression-free survival and 
perhaps  overall  survival  in  advanced  NSCLC.33–35 
When the agent selected for maintenance therapy is 
one that the patient has not previously received, it is 
referred to as “switch maintenance” therapy. In theory, 
switch maintenance may delay disease progression 
without  providing  overlapping  toxicity  or  cross-
  resistance with the agents used in the initial therapy. 
Vinorelbine was selected for study as maintenance 
therapy in one randomized trial due to its excellent 
tolerability with prolonged administration.
In this trial, patients with Stage IIIB or IV NSCLC 
were enrolled after responding to initial therapy with 
either 2 cycles of MIC (mitomycin, ifosfamide, and 
cisplatin) followed by radiation for IIIB patients or 
4 cycles of MIC for patients with advanced disease. 
181 out of 221 patients with advanced NSCLC who 
responded to initial therapy were then randomized 
to  receive  maintenance  therapy  with  vinorelbine 
(25 mg/m2 weekly for 6 months) or no further therapy. 
Vinorelbine was well tolerated with the most common 
grade  3–4  toxicities  consisting  of  leukocytopenia 
(36%), anemia (10%), infection (6%), peripheral neu-
ropathy (6%), and pulmonary toxicity (6%). There 
was, however, no benefit demonstrated in the vinore-
lbine maintenance arm in PFS, OS, or survival rates 
at 1 and 2 years.36
Subsequent and ongoing trials aimed at evaluat-
ing maintenance therapy in advanced NSCLC have 
since focused attention on newer agents in lieu of 
vinorelbine.
Vinorelbine in Elderly Patients  
with Advanced Disease
The median age at diagnosis for cancer of the lung and 
bronchus is 69 years of age, and more than one half 
of patients with lung cancer are older than 60 years at 
diagnosis. Thirty percent are 70 years or older.1 Older 
patients often have multiple and frequently interact-
ing co-morbidities that may decrease the tolerability 
of systemic therapies. Vinorelbine has been evaluated 
extensively in elderly patients as a single agent due to 
its favorable toxicity profile and until recently was a 
standard, front-line, agent in this patient population.
Vinorelbine  was  first  shown  to  be  an  effective 
agent in this population in the Elderly Lung Cancer 
Vinorelbine  Italian  Study  (ELVIS)  trial.  This  was 
a phase III trial that randomized 191 patients over 
70 years old with advanced NSCLC to receive BSC 
alone or BSC and vinorelbine 30 mg/m2 on days 1 
and 8, every 21 days for up to six cycles. The trial was 
terminated early because of slow accrual, and data for 
161 patients were analyzed. The median survival was 
significantly better in the chemotherapy group (28 vs. 
21 weeks; HR = 0.65, 95% CI 0.45–0.93; P = 0.03). 
The vinorelbine group also had a significantly supe-
rior one year survival rate (32% versus 14%; P value 
not reported). The quality of life analysis also favored 
the chemotherapy arm. The most common grade 3 or 
4 adverse effects experienced in the chemotherapy 
group were neutropenia (10%), leukocytopenia (7%), 
and anemia (16%).37
Oral anti-epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors (TKI’s), such as erlotinib 
and gefitinib, are standard, well-tolerated agents in the 
second-line setting for advanced NSCLC. After dem-
onstrating superiority over best supportive care in the 
elderly population, vinorelbine was compared to gefi-
tinib with the hypothesis that the oral agent would be Faller and Pandit
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as efficacious and less toxic, while improving quality 
of life. The INVITE trial was a phase II, open-label, 
parallel-group study that randomized 196 chemother-
apy naïve, elderly (age . 70) patients with advanced 
NSCLC to gefitinib alone (250 mg/day) or vinore-
lbine (30 mg/m2 on days 1 and 8 every 3 weeks). 
There was no difference in the two groups for PFS 
(HR = 1.19; 95% CI, 0.6 to 1.65) or OS (HR = 0.98; 
95% CI, 0.66 to 1.47). ORR and disease control rates 
were also similar between the two arms. Overall, the 
gefitinib group had superior QOL rates (24.3% vs. 
10.9%), and fewer treatment-related grade 3 or higher 
adverse events (12.8% vs. 41.7%).38
In the largest trial to examine vinorelbine in the 
treatment of elderly patients with advanced disease, 
vinorelbine was compared against and in combina-
tion with another well-tolerated to agent, gemcitabine. 
The Multi-center Italian Lung Cancer in the Elderly 
Study (MILES), an open-label phase III trial, random-
ized 698 elderly (70 years or above) with advanced 
NSCLC to receive V (vinorelbine 30 mg/m2), G (gem-
citabine 1200 mg/m2), or VG (vinorelbine 25 mg/m2 
and gemcitabine 1000 mg/m2). All treatments were 
given on days 1 and 8 every three weeks for a maxi-
mum of six cycles. Compared to the V and G alone 
arms, the VG combination did not improve overall 
survival. The HR for death for patients receiving VG 
compared to V was 1.17 (95% CI = 0.95 to 1.44); it 
was 1.06 (95% CI = 0.86 to 1.29) for the comparison 
of VG to G. Quality of life was similar across all three 
groups. The chemotherapy combination resulted in 
significantly more thrombocytopenia and abnormali-
ties in liver function testing than V alone. It resulted 
in more neutropenia, vomiting, fatigue, extravasation 
sequelae, cardiac toxicity, and constipation than G 
alone.39
The Southern Italy Cooperative Oncology Group 
and Interregional Association for the Study of Lung 
Carcinoma-Italy (SCIOG) trial also examined the VG 
regimen vs. V alone in elderly patients. They con-
ducted, a phase III trial, that randomized 120 elderly 
(70 years or more) patients with advanced NSCLC 
to receive V (vinorelbine 30 mg/m2 on days 1 and 
8 every 3 weeks) or VG (gemcitabine 1200 mg/m2 
and vinorelbine 30 mg/m2 on days 1 and 8 every 3 
weeks) with the primary endpoints of overall survival 
and quality of life. The overall response rate was 22% 
for the combination group compared to 15% for V 
alone. The VG regimen resulted in a superior median 
survival (29 vs. 18 weeks, P = , 0.01) and overall sur-
vival at 1 year (30% vs. 13%; P , 0.01) than V alone. 
The chemotherapy combination was also associated 
with an increased probability of being alive without 
symptom deterioration at 6 months (43% vs. 22%; 
P = 0.002) and an improved quality of life compared 
to V alone. Grade 3 or 4 neutropenia and thrombocy-
topenia occurred in 38% and 13% of patients in the 
VG group, respectively, compared to 28% and 8% in 
the V alone group. Severe emesis was also higher in 
the VG group (15% vs. 8%).40
The use of single-agent vinorelbine as first line 
therapy for advanced disease in the elderly popula-
tion is likely to fall out of favor, now, in light of recent 
data suggesting that it is inferior to the standard plati-
num doublet of carboplatin with paclitaxel (PC). At 
the 2010   American Society of Clinical Oncology’s 
annual meeting, results were presented from the IFCT-
0501 trial. In this trial, 451 patients aged 70 to 89 with 
advanced disease were randomized to therapy with 
a single chemotherapeutic agent (either vinorelbine 
30 mg/m2 or gemcitabine 1,150 mg/m2 on days 1 and 
8 every 21 days), or the PC combination (paclitaxel 
90 mg/m2 on days 1, 8, and 15 and carboplatin AUC 
6 on day 1 every 4 weeks). All patients who discon-
tinued study therapy due to progression or toxicity 
received erlotinib 150 mg orally daily. At the planned 
interim analysis the PC group had significantly supe-
rior median OS (10.4 vs. 6.2 months, P = 0.0001) and 
PFS (6.3 vs. 3.2 months, P , 0.0001) compared to 
the single-agent chemotherapy group. Grade 3 or 4 
hematological toxicities were higher for the PC group 
(54.1% vs. 17.9%). The final response, survival, and 
toxicity data have yet to be presented.41
Vinorelbine in Combination  
with Epidermal Growth Factor 
Receptor (EGFR) Targeted Therapy  
in Advanced NSCLC
The use of epidermal growth factor receptor (EGFR) 
targeted therapy is highly effective in selected subsets 
of patients with advanced NSCLC, especially those 
with EGFR activating mutations.42
Attempts to add the oral anti-EGFR TKI, gefitinib 
to vinorelbine or the VC combination were unsuccess-
ful in a phase I trial due to unacceptably high rates of 
myelosuppression and febrile neutropenia.43Faller and Pandit
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Cetuximab,  an  anti-EGFR  IgG-1  monoclonal 
antibody, was studied in addition to the VC regimen 
in the FLEX (First-Line ErbituX in lung cancer) trial. 
The FLEX trial was a large, phase III trial involving 
1125 patients with EFGR-expressing (by immunohis-
tochemistry), advanced NSCLC. Patients were ran-
domly assigned to receive VC (vinorelbine 25 mg/m2 
on days 1 and 8 and cisplatin 80 mg/m2 on day 1 
every 3-weeks up to six cycles) or VC plus cetuximab 
(Cetuximab at 400 mg/m2 on day 1, then 250 mg/m2 
weekly). Cetuximab was continued after the comple-
tion of chemotherapy until disease progression or the 
development of unacceptable toxicity. Patients who 
received VC with cetuximab had improved overall 
response rates (36% vs. 29%, P = 0.010) and sur-
vival (median OS 11.3 vs. 10.1 months; HR = 0.871; 
95% CI, 0.762–0.996; P = 0.044) compared to VC 
alone. The benefit was seen in all histological sub-
groups. There was no difference, however, in median 
PFS (4.8 months for both groups). The incorpora-
tion of cetuximab was associated with significantly 
higher rates of Grade 3 or 4 leukocytopenia (25% vs. 
19%), febrile neutropenia (22% vs. 15%), acne-like 
rash (10% vs.,1%), diarrhea (4–5% vs. 2–3%), and 
  infusion-related reactions (3–4% vs. 1%).44
Although  the  cetuximab  with  VC  regimen  in 
EGFR expressing advanced NSCLC has been incor-
porated in current guidelines on the management of   
NSCLC45 its use in the United States has been limited. 
The VC regimen has been questioned as an appropri-
ate comparator arm due to its inferior results when 
compared to DC in the TAX 326 trial described pre-
viously. In support of this argument, the addition of 
cetuximab to the more commonly used PC regimen 
was unable to produce a significant survival benefit.46 
Furthermore, the cost-  effectiveness of this regimen 
has  been    questioned.  One  analysis  estimated  the 
incremental cost effectiveness ratio for adding cetux-
imab to  chemotherapy to be the equivalent of roughly 
486,500  US  dollars  per  quality-adjusted  life  year 
gained.47
Conclusion
Lung  cancer  remains  the  leading  cause  of  can-
cer death in the United States. Its management is 
directed  by  the  stage  at  presentation.  For  patients 
who are   fortunate to undergo a complete resection, 
  platinum-based    adjuvant  chemotherapy,  has 
demonstrated a survival benefit. The combination of 
vinorelbine with   cisplatin has the most robust data in 
this setting.
For patients with locally advanced, unresectable 
disease,  dual  modality  therapy  combining  chemo-
therapy with radiotherapy remains the standard treat-
ment. Experience with vinorelbine for this indication 
is limited and requires further investigation.
In patients who present with advanced or recur-
rent disease, vinorelbine in combination with cispla-
tin (VC) is an effective regimen. In light of data from 
the TAX 326 trial demonstrating inferiority of the VC 
regimen to the combination of cisplatin and docetaxel, 
however, its use has fallen out of favor.33 In addition, 
vinorelbine has no demonstrated efficacy as a switch 
maintenance therapy for patients with advanced dis-
ease following a response to first-line therapy.
Lung cancer is a disease of advanced age with 
over 30% of the patients diagnosed after 70 years 
of age.1 Vinorelbine has been shown to be an effec-
tive and well tolerated agent for elderly patients with 
advanced disease. Recently presented data, however, 
from the IFCT-0501 trial, suggest that the standard, 
chemotherapy combination of paclitaxel and carbopl-
atin can be safely administered to this patient popula-
tion in the first-line setting, with greater efficacy than 
vinorelbine alone.42
The benefit of EGFR targeted therapy in selected 
patients with advanced NSCLC, specifically those 
with tumors harboring an EGFR activating   mutation, 
has been well established. Addition of the anti-EGFR 
monoclonal antibody, cetuximab, to the VC regimen 
results in a small, but significant survival benefit in 
patients with advanced disease as demonstrated in 
the FLEX trial.45 This combination has been incor-
porated into current guidelines on the management 
of NSCLC, but its use has been controversial, due to 
potential limitations in the design of the FLEX trial, 
as well as questions about its cost-effectiveness.
The management of NSCLC is an ever evolving 
topic  that  has  recently  seen  major  advancements. 
As the treatment of all cancer becomes increasing 
targeted and personalized, the role of vinorelbine is 
likely to change. At this time, based on its tolerability 
and proven efficacy, vinorelbine remains a vital agent 
in the treatment of NSCLC.vinorelbine in the treatment of non-small cell lung cancer
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